The pharmaceutical company Roche will buy the biotechnology company Carmot Therapeutics for a maximum total import of 3.1 billion dollars (2.847 million euros). The purchase agreement signed by the Swiss-based laboratory also includes the acquisition of three assets in the clinical stage for the development of drugs against obesity and diabetes.
Roche will make the first payment corresponding to the purchase process upon closing of the transaction, for a value of $2.7 billion. The company may or may not pay the remaining import depending on the returns obtained, in the form of payments of up to 400 million dollars (367 million euros) to Carmot shareholders.
By closing the transaction, the Swiss laboratory will be able to have access to Carmot’s project portfolio. This includes all of the American pharmaceutical company’s clinical and preclinical assets. As of this date, the company and its employees will become part of the pharmaceutical division of the health industry giant.
The purchase will close in 2024
The transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Closing of the operation is currently expected to occur in the first quarter of 2024.
“Obesity is a heterogeneous disease, contributing to many other diseases that together constitute a significant health burden worldwide,” said Thomas Schinecker, CEO of the Roche Group. “By combining Carmot’s portfolio with our portfolio of pharmaceutical products and our experience in diagnosis and product portfolio for cardiovascular and metabolic diseases, we aim to improve the level of care and positively impact the lives of patients,” he added.
The group, which has more than 2,500 employees in Spain, celebrated its 90 years of activity this year, looking to the future with the challenge of early access to innovation and the digital transformation of healthcare, as highlighted this Tuesday in Madrid at the event Shaping Innovation.
Roche activity since its foundation
Since Roche began its activity in Spain in Barcelona in 1933, under the name Roche Products, they have remembered that many things have changed and countless advances have been recorded in healthcare. However, Roche maintains the same objective, which is to “improve the health and quality of life of patients through constant innovation.”
To achieve this, it works in collaboration with regulators, managers, administrations, health professionals and patient organizations, among others, to research, develop and provide patients with diagnostic and therapeutic solutions to address the main health problems in areas such as oncology. hematology, ophthalmology, immunology or rare diseases from an increasingly personalized approach.
THE NAIS IS OFFICIAL EDITOR ON NAIS NEWS